- HK$52.02bn
- HK$171.29bn
- CNY575.17bn
Brief: Sinopharm Group Says FY Net Income RMB 9,053.76 Million
Escaping Hong Kong's value trap is far from cheap
Escaping Hong Kong's value trap is far from cheap
Sinopharm offers to take China-TCM private in nearly $3 bln deal (updated)
Sinopharm offers to take China-TCM private in nearly $3 bln deal
Brief: Blackrock Inc's Long Position In H-Shares Of Sinopharm Group Reduced To 6.94% On Jan 10 - HKEX
Brief: Sinopharm Says Nine Months Total Operating Revenue RMB445.92 Billion
Brief: Sinopharm Group Resolves To Elect Yu Qingming As Chairman
China's Sinopharm Group rises most in 5-1/2 months on solid H1 results
Brief: Sinopharm Group Says HY Revenue RMB300.95 Bln
Brief: Country Garden Removed As Hang Seng Index Constituent
Brief: JPMorgan's Long Position In H-Shares Of Sinopharm Falls To 4.82% - HKEX Filing
Brief: Sinopharm Group Announces Proposed Issue Of RMB15 Bln Corporate Bonds
Brief: Sinopharm Group Says Qtrly Total Operating Revenue RMB145.52 Bln
Brief: Lazard Asset Management's Long Position In H-Shares Of Sinopharm Group Rises To 7% - Filing
Pfizer signs strategic cooperation pact with China's Sinopharm
Brief: Sinopharm Group Says FY Profit Attributable RMB8.53 Bln
Brief: Elekta Signs Joint Venture With Sinopharm, To Increase Radiotherapy Adoption In China
Factbox: China mRNA vaccine development jumps into high gear